Similarly, alterations in RAS in AML/MDS are heterogeneous, differentially impact outcomes, and are likely influenced by the presence of concurrent mutations such as BCOR, leading to resistance to chemotherapy, venetoclax, azacitidine, and targeted therapy such as tyrosine kinase and FLT3 inhibitors [40,41]. Here, FLT3 is linked to myelodysplastic syndrome.